The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030.
  Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access   Roots Analysis is pleased to announce the publication of its recent study, titled, “Liquid Biopsy and Other Non-Invasive Cancer...
0 Comments 0 Shares